Literature DB >> 31396334

Snail expression contributes to temozolomide resistance in glioblastoma.

Huaxin Liang1, Guangyong Chen1, Jiayan Li2, Fuwei Yang1.   

Abstract

Glioblastoma (GBM) is one of most malignancy tumors worldwide. Temozolomide (TMZ) is an important chemotherapy drug in GBM therapy. However, acquired TMZ-resistance frequently happens in GBM therapy and leads to high percentage of GBM recurrence. In our study, we demonstrated that Snail is upregulated in recurrent GBM tumors, and promotes the GBM cells resistant to TMZ induced apoptosis. Enhanced expression of Snail compromises the apoptosis induced by TMZ, and increases the cell migration and invasion. Reversely, depletion of Snail by siRNA has the opposite effects. In addition, we confirmed that the expression of Snail is modulated by STAT3 activation, since phospho-STAT3 level is relatively higher in recurrent GBM tumors and TMZ resistant cells. Knockdown of STAT3 turns down the expression of Snail in protein and mRNA level, and thereby sensitized the resistant GBM cells to TMZ treatment. Interestingly, the activation of STAT3 in GBM resistant cells is modulated by IL-6 secretion. Suppression of IL-6 abandons the STAT3 activation, and reduces its binding with Snail promoter. Inhibition of IL-6 by its antibody enhanced the killing effects of TMZ both in vivo and in vitro. Overall, our results provided a rational to overcome the TMZ resistant in GBM treatment by targeting IL-6-STAT3-Snail pathway.

Entities:  

Keywords:  IL-6; STAT3; Snail; glioblastoma; temozolomide

Year:  2019        PMID: 31396334      PMCID: PMC6684932     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  36 in total

1.  Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells.

Authors:  Shaik Ohidar Rahaman; Phyllis C Harbor; Olga Chernova; Gene H Barnett; Michael A Vogelbaum; S Jaharul Haque
Journal:  Oncogene       Date:  2002-12-05       Impact factor: 9.867

Review 2.  Epithelial-mesenchymal transitions in tumour progression.

Authors:  Jean Paul Thiery
Journal:  Nat Rev Cancer       Date:  2002-06       Impact factor: 60.716

Review 3.  The Snail genes as inducers of cell movement and survival: implications in development and cancer.

Authors:  Alejandro Barrallo-Gimeno; M Angela Nieto
Journal:  Development       Date:  2005-07       Impact factor: 6.868

Review 4.  Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis.

Authors:  Jing Yang; Robert A Weinberg
Journal:  Dev Cell       Date:  2008-06       Impact factor: 12.270

5.  A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo.

Authors:  A Iwamaru; S Szymanski; E Iwado; H Aoki; T Yokoyama; I Fokt; K Hess; C Conrad; T Madden; R Sawaya; S Kondo; W Priebe; Y Kondo
Journal:  Oncogene       Date:  2006-10-16       Impact factor: 9.867

6.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.

Authors:  W K Yung; M D Prados; R Yaya-Tur; S S Rosenfeld; M Brada; H S Friedman; R Albright; J Olson; S M Chang; A M O'Neill; A H Friedman; J Bruner; N Yue; M Dugan; S Zaknoen; V A Levin
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

7.  Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity.

Authors:  James Turkson; Shumin Zhang; Jay Palmer; Heidi Kay; Joseph Stanko; Linda B Mora; Said Sebti; Hua Yu; Richard Jove
Journal:  Mol Cancer Ther       Date:  2004-12       Impact factor: 6.261

8.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

9.  Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators.

Authors:  Hui-Wen Lo; Xinyu Cao; Hu Zhu; Francis Ali-Osman
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

Review 10.  Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.

Authors:  Mohit Trikha; Robert Corringham; Bernard Klein; Jean-François Rossi
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

View more
  5 in total

1.  Knockdown of DEPDC1B inhibits the development of glioblastoma.

Authors:  Xu Chen; Zheng-Qian Guo; Dan Cao; Yong Chen; Jian Chen
Journal:  Cancer Cell Int       Date:  2020-07-15       Impact factor: 5.722

Review 2.  SNAIL1: Linking Tumor Metastasis to Immune Evasion.

Authors:  Xiaolong Tang; Xue Sui; Liang Weng; Yongshuo Liu
Journal:  Front Immunol       Date:  2021-11-30       Impact factor: 7.561

3.  Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review.

Authors:  Neha Singh; Alexandra Miner; Lauren Hennis; Sandeep Mittal
Journal:  Cancer Drug Resist       Date:  2021-03-19

4.  Epithelial-Mesenchymal Transition: Role in Cancer Progression and the Perspectives of Antitumor Treatment.

Authors:  A V Gaponova; S Rodin; A A Mazina; P V Volchkov
Journal:  Acta Naturae       Date:  2020 Jul-Sep       Impact factor: 1.845

5.  MicroRNA-221 promotes tumor progression by targeting HHIP in human glioblastoma.

Authors:  Liang Chang; Lisheng Yin; Dongzhi Zhang; Chao Wang; Guofu Li; Chunlei Tan; Xuexin Zhang; Jun Su
Journal:  Transl Cancer Res       Date:  2021-02       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.